Huvepharma Introduces New Necrotic Enteritis Vaccine Developed by Curtiss Healthcare, Inc.

Huvepharma, Inc., a pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products, has introduced AVERT NE, an innovative new vaccine to help control necrotic enteritis (NE) due to Clostridium perfringens Type A.

The company said AVERT NE utilizes proprietary and unique recombinant attenuated Salmonella vaccine (RASV) technology from UF startup and UF Innovate | Sid Martin Biotech resident Curtiss Healthcare, Inc. as the delivery platform to elicit an immune response to protect chickens from NE.

“The relationship between Curtiss Healthcare and Huvepharma represents the ideal example of bringing innovative, science-based technology to the market to solve real-world problems,” said Dr. Bob Nordgren, chief research and development officer of Curtiss Healthcare. “The RASV platform is the brainchild of National Academy of Sciences member Dr. Roy Curtiss. He recognized the value of applying advanced enabling recombinant technology to modify Salmonella to serve as a vector to protect against a range of diseases. We look forward to continuing our collaboration with Huvepharma to find additional opportunities to leverage this exciting technology to help improve animal health.”

Curtiss Healthcare is a biopharmaceutical company developing a platform of new vaccines designed to help make the world a safer place through technologies that improve food quality and safety and help treat and prevent serious infections in humans and animals.

Learn more about Huvepharma Introduces New Necrotic Enteritis Vaccine Developed by UF Innovate | Sid Martin Biotech Resident Curtiss Healthcare, Inc.